Krystal Biotech (KRYS) Short Interest Ratio & Short Volume $138.21 +2.13 (+1.57%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$138.36 +0.16 (+0.11%) As of 06/10/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Krystal Biotech Short Interest DataKrystal Biotech (KRYS) has a short interest of 2.60 million shares, representing 10.52% of the float (the number of shares available for trading by the public). This marks a 9.70% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.7, indicating that it would take 7.7 days of the average trading volume of 306,928 shares to cover all short positions.Current Short Interest2,600,000 sharesPrevious Short Interest2,370,000 sharesChange Vs. Previous Month+9.70%Dollar Volume Sold Short$338.86 millionShort Interest Ratio7.7 Days to CoverLast Record DateMay 15, 2025Outstanding Shares28,899,000 sharesShort Percent of Float10.52%Today's Trading Volume240,919 sharesAverage Trading Volume306,928 sharesToday's Volume Vs. Average78% Short Selling Krystal Biotech? Sign up to receive the latest short interest report for Krystal Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKRYS Short Interest Over TimeKRYS Days to Cover Over TimeKRYS Percentage of Float Shorted Over Time Krystal Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20252,600,000 shares $338.86 million +9.7%10.5%7.7 $130.33 4/30/20252,370,000 shares $402.62 million -2.1%N/A7.4 $169.88 4/15/20252,420,000 shares $409.29 million -10.7%9.8%8.5 $169.13 3/31/20252,710,000 shares $488.61 million +0.4%11.0%9.5 $180.30 3/15/20252,700,000 shares $484.33 million -2.2%10.9%9.9 $179.38 2/28/20252,760,000 shares $494.73 million -13.5%11.2%9.9 $179.25 2/15/20253,190,000 shares $488.84 million +6.0%12.9%11.9 $153.24 1/31/20253,010,000 shares $480.82 million -7.4%N/A11.5 $159.74 1/15/20253,250,000 shares $475.93 million -3.6%N/A12.2 $146.44 12/31/20243,370,000 shares $527.94 million -8.9%N/A13.6 $156.66 Get the Latest News and Ratings for KRYS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. 12/15/20243,700,000 shares $605.47 million +1.4%N/A15.4 $163.64 11/30/20243,650,000 shares $720.58 million +1.4%N/A15.5 $197.42 11/15/20243,600,000 shares $614.66 million +4.4%N/A15.7 $170.74 10/31/20243,450,000 shares $595.23 million -2.5%N/A16.1 $172.53 10/15/20243,540,000 shares $631.75 million +0.6%N/A15.6 $178.46 9/30/20243,520,000 shares $640.75 million -4.1%N/A13.9 $182.03 9/15/20243,670,000 shares $739.80 million -0.5%N/A12.9 $201.58 8/31/20243,690,000 shares $719.99 million +4.2%N/A9.5 $195.12 8/15/20243,540,000 shares $686.69 million +1.1%N/A9.1 $193.98 7/31/20243,500,000 shares $729.61 million -4.6%N/A8.8 $208.46 7/15/20243,670,000 shares $762.92 million +4.6%N/A9.4 $207.88 6/30/20243,510,000 shares $644.58 million +21.0%N/A9.1 $183.64 6/15/20242,900,000 shares $515.56 million +7.8%N/A7.7 $177.78 5/31/20242,690,000 shares $430.53 million -4.3%N/A8.6 $160.05 5/15/20242,810,000 shares $458.56 million +8.5%N/A7.5 $163.19 4/30/20242,590,000 shares $396.58 million +5.7%N/A6.6 $153.12 4/15/20242,450,000 shares $415.89 million +12.9%N/A6.2 $169.75 3/31/20242,170,000 shares $386.11 million -3.1%N/A5.5 $177.93 3/15/20242,240,000 shares $387.48 million -10.8%N/A5.8 $172.98 2/29/20242,510,000 shares $400.27 million +1.6%N/A6.5 $159.47 2/15/20242,470,000 shares $280.05 million +21.7%N/A7.3 $113.38 1/31/20242,030,000 shares $225.84 million +3.1%N/A6.6 $111.25 1/15/20241,970,000 shares $252.87 million -9.2%N/A6.3 $128.36 12/31/20232,170,000 shares $269.21 million +11.3%N/A7.1 $124.06 12/15/20231,950,000 shares $225.73 million -8.0%N/A6.4 $115.76 11/30/20232,120,000 shares $220.97 million +2.4%N/A6.8 $104.23 11/15/20232,070,000 shares $206.09 million -1.4%N/A6.8 $99.56 10/31/20232,100,000 shares $245.43 million +7.1%N/A7.1 $116.87 10/15/20231,960,000 shares $223.01 million -0.5%N/A7.4 $113.78 9/30/20231,970,000 shares $228.52 million +23.9%N/A7.4 $116.00The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 9/15/20231,590,000 shares $191.07 million +6.0%N/A5.9 $120.17 8/31/20231,500,000 shares $186.72 million -2.6%N/A5.7 $124.48 8/15/20231,540,000 shares $187.82 million +15.8%N/A5.3 $121.96 7/31/20231,330,000 shares $171.70 million -7.6%N/A4.1 $129.10 7/15/20231,440,000 shares $181.83 million +6.7%6.8%4.7 $126.27 6/30/20231,350,000 shares $158.49 million +3.1%6.4%4.5 $117.40 6/15/20231,310,000 shares $163.37 million +10.1%6.2%4.3 $124.71 5/31/20231,190,000 shares $140.24 million +3.5%5.6%4.3 $117.85 5/15/20231,150,000 shares $103.56 million -0.9%5.5%4.4 $90.05 4/30/20231,160,000 shares $97.44 million -7.2%5.5%5.7 $84.00 4/15/20231,250,000 shares $107.98 million +4.2%6.0%6.4 $86.38 3/31/20231,200,000 shares $96.07 million +5.3%5.8%5.9 $80.06 3/15/20231,140,000 shares $83.80 million -4.2%5.5%5.9 $73.51 2/28/20231,190,000 shares $97.47 million +6.3%5.7%6.3 $81.91 2/15/20231,120,000 shares $82.33 million +6.7%5.4%6.5 $73.51 1/31/20231,050,000 shares $87.28 million -7.1%5.1%6.1 $83.12 1/15/20231,130,000 shares $93.73 million +14.4%5.4%6.5 $82.95 12/30/2022988,100 shares $78.28 million -10.2%4.8%5.9 $79.22 12/15/20221,100,000 shares $86.24 million -9.1%5.3%6.9 $78.40 11/30/20221,210,000 shares $94.07 million -3.2%5.9%7.8 $77.74 11/15/20221,250,000 shares $96.51 million -4.6%6.1%7.7 $77.21 10/31/20221,310,000 shares $100.22 million +3.2%6.4%7.9 $76.50 10/15/20221,270,000 shares $83.83 million -3.1%6.2%7.6 $66.01 9/30/20221,310,000 shares $91.31 million +7.4%6.4%7.9 $69.70 9/15/20221,220,000 shares $86.97 million -4.7%6.3%7.3 $71.29 8/31/20221,280,000 shares $89.74 million -5.9%6.6%7.2 $70.11 8/15/20221,360,000 shares $105.48 million -0.7%7.0%7.9 $77.56 7/31/20221,370,000 shares $99.43 million -1.4%7.0%7.5 $72.58 7/15/20221,390,000 shares $100.66 million -10.9%7.1%7.7 $72.42 6/30/20221,560,000 shares $102.43 million -2.5%7.9%8.6 $65.66 6/15/20221,600,000 shares $85.34 million +0.6%8.1%8.4 $53.34 5/31/20221,590,000 shares $93.62 million -1.2%8.1%7.8 $58.88 5/15/20221,610,000 shares $90.77 million +2.6%8.2%7.6 $56.38 4/30/20221,570,000 shares $95.16 million -7.1%8.1%7.4 $60.61 4/15/20221,690,000 shares $122.51 million +5.0%8.7%8 $72.49 3/31/20221,610,000 shares $107.13 million +17.5%8.4%7.2 $66.54 3/15/20221,370,000 shares $84.98 million +13.2%7.1%6.3 $62.03 2/28/20221,210,000 shares $76.90 million +4.3%6.4%5.2 $63.55 2/15/20221,160,000 shares $78.11 million +9.4%N/A2.6 $67.34 1/31/20221,060,000 shares $62.54 million -1.9%5.6%2.4 $59.00 1/15/20221,080,000 shares $67.26 million +4.9%5.7%2.4 $62.28 12/31/20211,030,000 shares $72.05 million -25.4%5.4%2.4 $69.95 12/15/20211,380,000 shares $99.98 million -37.6%7.3%3.3 $72.45 11/30/20212,210,000 shares $178.02 million +6.8%12.3%5.7 $80.55 11/15/20212,070,000 shares $98.22 million +12.5%12.9%13.6 $47.45 10/29/20211,840,000 shares $92.17 million +5.8%11.5%14.2 $50.09 10/15/20211,740,000 shares $84.77 million +13.0%10.8%15 $48.72 9/30/20211,540,000 shares $80.40 million -0.7%9.6%13.6 $52.21 9/15/20211,550,000 shares $86.89 million -4.3%9.7%12.5 $56.06 8/31/20211,620,000 shares $93.86 million +12.5%10.1%12.6 $57.94The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 8/13/20211,440,000 shares $80.90 million +7.5%9.0%11.6 $56.18 7/30/20211,340,000 shares $78.31 million +24.1%8.4%10.9 $58.44 7/15/20211,080,000 shares $67.46 million -1.8%6.8%9.3 $62.46 6/30/20211,100,000 shares $74.80 million -4.4%6.9%10.1 $68.00 6/15/20211,150,000 shares $72.91 million -0.9%7.2%11.8 $63.40 5/28/20211,160,000 shares $75.68 million -4.1%7.3%11.5 $65.24 5/14/20211,210,000 shares $75.67 million -2.4%7.6%10.7 $62.54 4/30/20211,240,000 shares $99.35 million +3.3%7.8%9.2 $80.12 4/15/20211,200,000 shares $89.72 million -3.2%7.5%8 $74.77 3/31/20211,240,000 shares $90.43 million +6.9%7.9%8 $72.93 3/15/20211,160,000 shares $96.06 million -2.5%7.4%7.1 $82.81 2/26/20211,190,000 shares $93.87 million +10.2%7.9%7.3 $78.88 2/12/20211,080,000 shares $74.19 million -10.7%7.2%6.5 $68.69 1/29/20211,210,000 shares $85.51 million -6.2%8.1%7.3 $70.67 1/15/20211,290,000 shares $85.58 million -5.8%9.6%8.6 $66.34 12/31/20201,370,000 shares $82.76 million +2.2%10.2%9.3 $60.41 12/15/20201,340,000 shares $78.26 million -2.2%10.0%9 $58.40 11/30/20201,370,000 shares $66.94 million -4.2%10.2%9.8 $48.86 11/15/20201,430,000 shares $59.89 million -7.1%10.7%10.6 $41.88 10/30/20201,540,000 shares $69.79 million -11.0%11.5%12.1 $45.32 10/15/20201,730,000 shares $86.60 million -3.9%13.0%13.6 $50.06 9/30/20201,800,000 shares $77.49 million +8.4%13.5%14.1 $43.05 9/15/20201,660,000 shares $76.71 million +1.8%12.4%11.7 $46.21 8/31/20201,630,000 shares $77.93 million +4.5%12.3%10.8 $47.81 8/14/20201,560,000 shares $66.46 million -3.7%11.7%9.6 $42.60 7/31/20201,620,000 shares $66.89 million +2.5%12.2%8.5 $41.29 7/15/20201,580,000 shares $63.37 million No Change11.9%8.5 $40.11 6/30/20201,580,000 shares $65.25 million +29.5%12.7%7.9 $41.30 6/15/20201,220,000 shares $55.47 million +3.4%9.8%6.3 $45.47 KRYS Short Interest - Frequently Asked Questions What is Krystal Biotech's current short interest? Short interest is the volume of Krystal Biotech shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 2,600,000 shares of KRYS short. 10.52% of Krystal Biotech's shares are currently sold short. Learn More on Krystal Biotech's current short interest. What is a good short interest ratio for Krystal Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KRYS shares currently have a short interest ratio of 8.0. Learn More on Krystal Biotech's short interest ratio. Which institutional investors are shorting Krystal Biotech? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Krystal Biotech: Jane Street Group LLC, Nantahala Capital Management LLC, Caption Management LLC, Nomura Holdings Inc., Walleye Trading LLC, Walleye Capital LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Krystal Biotech? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.52% of Krystal Biotech's floating shares are currently sold short. Is Krystal Biotech's short interest increasing or decreasing? Krystal Biotech saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,600,000 shares, an increase of 9.7% from the previous total of 2,370,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Krystal Biotech's short interest compare to its competitors? 10.52% of Krystal Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Krystal Biotech: Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S (0.45%), Summit Therapeutics Inc. (29.82%), Dr. Reddy's Laboratories Limited (1.83%), Ascendis Pharma A/S (10.33%), Moderna, Inc. (19.64%), Viatris Inc. (4.53%), Qiagen (2.81%), Blueprint Medicines Co. (9.26%), Roivant Sciences Ltd. (11.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Krystal Biotech stock? Short selling KRYS is an investing strategy that aims to generate trading profit from Krystal Biotech as its price is falling. KRYS shares are trading up $2.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Krystal Biotech? A short squeeze for Krystal Biotech occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KRYS, which in turn drives the price of the stock up even further. How often is Krystal Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KRYS, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies ITCI Short Interest Data GMAB Short Interest Data SMMT Short Interest Data RDY Short Interest Data ASND Short Interest Data MRNA Short Interest Data VTRS Short Interest Data QGEN Short Interest Data BPMC Short Interest Data ROIV Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KRYS) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
